BioSpace News Archive

Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today at Vaxart’s key opinion leader event that new data obtained from its Phase I COVID-19 trial added to the evidence suggesting that VXA-CoV2-1,

Protagonist Therapeutics, Inc. reported that on April 30, 2021, it issued an inducement award to Ramesh Bhatt, the Company’s recently hired Vice President, Discovery Biology and Translational Research, in accordance with the terms of Dr. Bhatt’s employment offer letter.

Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX: VMD.TO and NASDAQ:VMD), a home medical equipment supplier that provides post-acute respiratory care services in the United States, announced today that it has reported its financial results for the three months ended March 31, 2021. Operational highlights (all dollar amounts are USD):

Trellus Health, a leading resilience-driven connected health solution for chronic conditions, announced several important additions to its executive team and board of directors.

Syneos Health, Inc., the only fully integrated biopharmaceutical solutions organization, announced the pricing of the previously announced underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 7,000,000 shares of the Company’s common stock.

2021 Q1 HIGHLIGHTS compared to the corresponding period of 2020: - Revenues were $13.2 million, an increase of 40% - Pre-tax net income of $6.0 million, an increase of $2.5 million, or 74%, compared to $3.5 million - Net income was $4.9 million, or $0.73 per basic share and $0.60 per diluted share, compared to $2.7 million, or $0.41 per basic share and $0.33 per diluted share - Cash at March 31, 2021 increased to $26.5 million from $11.2 million

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced that management will present a company update at the following virtual investor conferences:

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that a new article published in the Journal of Medical Economics reviews the two-year PAD-related health care costs of patients enrolled in the LIBERTY 360° trial.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2021 and provided an operating forecast and program updates.

Amedisys, Inc., a leading provider of quality home health, hospice and personal care, has closed on its acquisition of regulatory assets that allow the Company to conduct home health care operations in Randolph County, N.C.